

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-22 (Cancelled).

Claim 23 (New): A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering to a mammal in need thereof:

- (i) 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form;
- (ii) an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue ; and
- (iii) an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form.

Claim 24 (New): A method according to claim 23, wherein the insulin secretagogue is a sulphonylurea insulin secretagogue.

Claim 25 (New): A method according to claim 24, wherein the sulphonylurea insulin secretagogue is glibenclamide, glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide, or glycylamide.

Claim 26 (New): A method according to claim 23, wherein the insulin secretagogue is repaglinide.

Claim 27 (New): A method according to claim 23, which comprises administering 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 28 (New): A method according to claim 23, which comprises administering 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 29 (New): A method according to claim 23, which comprises administering 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 30 (New): A method according to claim 23, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 31 (New): A method according to claim 23, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7, or 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 32 (New): A method according to claim 31, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 33 (New): A method according to claim 31, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 34 (New): A method according to claim 31, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 35 (New): A method according to claim 31, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 36 (New): A method according to claim 31, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

Claim 37 (New): A method according to claim 31, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

Claim 38 (New): A method according to claim 23, wherein said unit dosage form is a tablet or a capsule.

Claim 39 (New): A method according to claim 23, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an insulin secretagogue, and metformin, in a pharmaceutically acceptable form.

Claim 40 (New): A method according to claim 39, which comprises administering a formulation which comprises said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an insulin secretagogue, and metformin, in a pharmaceutically acceptable form.

Claim 41 (New): A method according to claim 39, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an insulin secretagogue, and metformin, in a pharmaceutically acceptable form.

Claim 42 (New): A method according to claim 23, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, an insulin secretagogue, and metformin, in a pharmaceutically acceptable form.

Claim 43 (New): A method according to claim 23, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable salt form.

Claim 44 (New): A method according to claim 43, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 45 (New): A method according to claim 23, wherein said pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable solvate form.

Claim 46 (New): A method according to claim 23, wherein said pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 47 (New): A method according to claim 45, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 48 (New): A method according to claim 46, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 49 (New): A method according to claim 23, which comprises administering a tablet or a capsule comprising 1 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue, and said effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form.

Claim 50 (New): A method according to claim 23, which comprises administering a tablet or a capsule comprising a pharmaceutically acceptable salt of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue, and said effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form.

Claim 51 (New): A method according to claim 23, which comprises administering a tablet or a capsule comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue, and said effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form.

Claim 52 (New): A method for the treatment of Type II diabetes in a mammal, which method comprises administering to a mammal in need thereof:

(i) 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form;

(ii) an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue ; and

(iii) an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form.

Claim 53 (New): A method according to claim 52, wherein the insulin secretagogue is a sulphonylurea insulin secretagogue.

Claim 54 (New): A pharmaceutical composition comprising 1 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue; an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form; and a pharmaceutically acceptable carrier therefor.

Claim 55 (New): A pharmaceutical composition comprising 1 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue; an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form; and a pharmaceutically acceptable carrier therefor.

Claim 56 (New): A pharmaceutical composition comprising 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue; an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form; and a pharmaceutically acceptable carrier therefor.

Claim 57 (New): A pharmaceutical composition comprising 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically

acceptable amount of an insulin secretagogue; an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form; and a pharmaceutically acceptable carrier therefor.

Claim 58 (New): A pharmaceutical composition comprising 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of an insulin secretagogue; an effective, non-toxic and pharmaceutically acceptable amount of metformin, in a pharmaceutically acceptable form; and a pharmaceutically acceptable carrier therefor.

Claim 59 (New): A pharmaceutical composition according to any one of claims 54-58, wherein the insulin secretagogue is a sulphonylurea insulin secretagogue.

Claim 60 (New): A pharmaceutical composition according to any one of claims 54-58, wherein said pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable salt form.

Claim 61 (New): A pharmaceutical composition according to claim 59, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 62 (New): A pharmaceutical composition according to any one of claims 54-58, wherein said pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable solvate form.

Claim 63 (New): A pharmaceutical composition according to any one of claims 54-58, wherein said pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 64 (New): A pharmaceutical composition according to claim 62, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 65 (New): A pharmaceutical composition according to claim 63, wherein said pharmaceutically acceptable solvate is a hydrate.